|
Pipeline to Partnerships (P2P)
| Category/Phase: Diabetes/Renal/Hepatic / Research |
  represents column sort |
|
|
Title
|
Company Name
|
Platform /
Modality
|
Target
|
Investor/Partner
Relations
|
| Biological Fluid Separation Apparatus |
EMV Technologies, LLC |
Point of Care |
|
VC, Licensing, Strategic Partner |
| Development of a Novel Anti-Diabetes Agent |
Preventive Nutrient Co., Inc |
Other (Anti-disbetes sgent) |
Treatment of Type 2 Diabetes |
Strategic Partner |
| Gold Nanoparticle X-ray Contrast Agent |
Nanoprobes, Incorporated |
Imaging |
|
Strategic Partner |
| Human Mini-Tumor Bioassay Platform to Identify Drug Candidates & Patient Profiling |
Vivo Biosciences Inc |
Biologic |
Preclinical Drug discovery, Patient Chemo-prediction |
VC, Licensing, Manufacturing, Strategic Partner |
| Infection Resistant Catheter |
Whalen Biomedical Inc. |
Other |
|
VC, Strategic Partner, Other |
| Long-acting Native GLP-1 Frmulation for the Treatment of Diabetes |
PharmaIN, Ltd. |
Biologic |
GLP-1 receptor (glucagon-like peptide 1 receptor) |
VC, Licensing, Strategic Partner |
| Rapid and Accurate Determination of Non-Radioactive Iodinated GFR Markers |
Lynntech, Inc. |
Point of Care |
Non-Radio Active Iodinated GFR Markers & Contrast Agents |
VC, Licensing, Manufacturing, Strategic Partner |
|
